EPA090 | Factors associated with SARS-CoV2 vaccination acceptance in people with HIV participating in the SCAPE-HIV study | E-poster | SARS-Cov2 vaccines |
EPA091 | Immunogenicity of mRNA-1273 COVID-19 vaccination in PLWH after inadequate primary vaccination response | E-poster | SARS-Cov2 vaccines |
EPA092 | SARS-CoV-2 Omicron Spike recognition by plasma fromindividuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses | E-poster | SARS-Cov2 vaccines |
EPA093 | Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected Individuals not responding to the Ad26.COV2.S vaccine | E-poster | SARS-Cov2 vaccines |
EPA094 | Characterization of serum and mucosal SARS-CoV-2-antibodies in HIV-1 infected subjects after BNT162b2 mRNA vaccination or SARS-CoV-2 infection | E-poster | SARS-Cov2 vaccines |
EPB001 | Factors influencing immune restoration in people living with HIV/AIDS | E-poster | Impact of co-factors (e.g., viral clade, tropism, genetic factors) on disease progression |
EPB002 | Reduced selection of unfavourable HLA-I in mother-to-child HIV transmission in KwaZulu Natal, South Africa | E-poster | Impact of co-factors (e.g., viral clade, tropism, genetic factors) on disease progression |
EPB004 | The relationship between infant mortality, survival rates, and HIV status among Ethiopian infants born to HIV-positive mothers within their first year | E-poster | Morbidity, mortality and life expectancy in clinical research |
EPB005 | The CIHR Canadian HIV Trials Network: 32 years strong in improving prevention, treatment and management for people living with HIV in Canada through the implementation of high-quality research | E-poster | Morbidity, mortality and life expectancy in clinical research |
EPB006 | Improving short-term mortality of people living with HIV admitted to the intensive care unit: a 20-year study (2000-2019) | E-poster | Morbidity, mortality and life expectancy in clinical research |